Clinical journal of the American Society of Nephrology : CJASN
-
Clin J Am Soc Nephrol · Jan 2019
Randomized Controlled Trial Multicenter StudyEffects of Molidustat in the Treatment of Anemia in CKD.
The efficacy and safety of molidustat, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, have been evaluated in three 16-week, phase 2b studies in patients with CKD and anemia who are not on dialysis (DaIly orAL treatment increasing endOGenoUs Erythropoietin [DIALOGUE] 1 and 2) and in those who are on dialysis (DIALOGUE 4). ⋯ The overall phase 2 efficacy and safety profile of molidustat in patients with CKD and anemia enables the progression of its development into phase 3.